MDT

87.68

+0.05%↑

115.45

+1.23%↑

VEEV

151

-4.46%↓

HQY

80.47

-2.25%↓

TLRY

6.68

+1.98%↑

MDT

87.68

+0.05%↑

115.45

+1.23%↑

VEEV

151

-4.46%↓

HQY

80.47

-2.25%↓

TLRY

6.68

+1.98%↑

MDT

87.68

+0.05%↑

115.45

+1.23%↑

VEEV

151

-4.46%↓

HQY

80.47

-2.25%↓

TLRY

6.68

+1.98%↑

MDT

87.68

+0.05%↑

115.45

+1.23%↑

VEEV

151

-4.46%↓

HQY

80.47

-2.25%↓

TLRY

6.68

+1.98%↑

MDT

87.68

+0.05%↑

115.45

+1.23%↑

VEEV

151

-4.46%↓

HQY

80.47

-2.25%↓

TLRY

6.68

+1.98%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

15.31 2.13

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.98

Max

15.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -12M
Darbuotojai	37
EBITDA	-2.1M -12M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+104.21% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-96M 1.2B
Ankstesnė atidarymo kaina	13.18
Ankstesnė uždarymo kaina	15.31

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026-04-09 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-04-09 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-09 23:07; UTC

Rinkos pokalbiai

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026-04-09 22:54; UTC

Rinkos pokalbiai

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026-04-09 20:57; UTC

Svarbiausios naujienos

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026-04-09 20:55; UTC

Uždarbis

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026-04-09 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-09 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026-04-09 20:25; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026-04-09 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-09 19:30; UTC

Svarbiausios naujienos

How Digital Currencies Have Helped Iran -- WSJ

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

104.21% į viršų

12 mėnesių prognozė

Vidutinis 32 USD 104.21%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.